Converting from a Spray-Dried Dispersion to a KinetiSol Formulation in <5 Months
A Phase 2 oral drug candidate formulated as a spray-dried dispersion faced limitations in bioavailability, pill burden, and solvent-intensive manufacturing. In less than five months, AustinPx converted the program to a KinetiSol™ formulation, achieving a 5x increase in AUC, reducing manufacturing time by 67%, and eliminating organic solvents and secondary processing steps. The result was…
Read MoreData-Driven Development of Clofazimine: A High-Drug Load Pediatric Mini-Tablet
The development of clofazimine pediatric mini-tablets demonstrates a data-driven approach to pharmaceutical development. By leveraging predictive tools and iterative design, AustinPx transformed a formulation-challenged compound into a scalable, patient-friendly product suitable for clinical trials.
Read MoreUsing KinetiSol Technology to Improve an Abandoned Prostate Cancer Medication (Galeterone)
In 2019, there were approximately 175,000 new cases of prostate cancer, contributing to 10% of male cancer-related fatalities. Galeterone, a novel prostate cancer candidate treatment, was discontinued after a Phase III clinical trial due to lack of efficacy. This Case Study explores how KinetiSol outperforms Spray Dried ASD and helped bring Galeterone to market.
Read More